Memantine and borderline personality disorder

Phase 3

• Conditions: Borderline personality disorder.; Borderline personality disorder; F60.3

• Registration Number: IRCT20210106049948N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Women or men between the ages of 16 and 45 who have been diagnosed with BPD using the BEST tool for the disease.

Exclusion Criteria

Clinical evidence of any pathology in the central nervous system, neurological disorders, head injuries, epilepsy or history of seizures
Pregnancy or breastfeeding
Taking medications that may interact with memantine

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum levels of memantine. Timepoint: Measurement of serum levels of memantine at the beginning of the study (before the intervention) and at the end of the treatment period. Method of measurement: High Performance Liquid Chromatograpy.;Symptoms. Timepoint: beginning of the study (before the intervention) and At the end of weeks 2, 4, 6 and 8. Method of measurement: The Best test.

Secondary Outcome Measures

Name	Time	Method
umber of suicides. Timepoint: At the beginning of the study (before the intervention) and at the end of the intervention. Method of measurement: interview with patients.